All Stories

  1. Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans

    Article • Toxicological Sciences, October 2019, Oxford University Press (OUP)

    Ronald N. Hines

  2. A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes

    Article • Chemical Research in Toxicology, July 2019, American Chemical Society (ACS)

    Ronald N. Hines

  3. Developmental Expression of the Cytosolic Sulfotransferases in Human Liver

    Article • Drug Metabolism and Disposition, March 2019, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  4. Construction of a per- and polyfluoroalkyl substances (PFAS) screening library

    Article • Environmental Health Perspectives, January 2019, Environmental Health Perspectives

    Dr Antony John Williams, Ronald N. Hines

  5. The Impact of Scaling Factor Variability on Risk-Relevant Pharmacokinetic Outcomes in Children: A Case Study Using Bromodichloromethane (BDCM)

    Article • Toxicological Sciences, September 2018, Oxford University Press (OUP)

    Ronald N. Hines

  6. Application of epigenetic data in human health risk assessment

    Article • Current Opinion in Toxicology, October 2017, Elsevier

    Ronald N. Hines

  7. Ontogeny of human hepatic CYP2C8 and CYP1A2

    Article • Drug Metabolism and Disposition, February 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  8. FutureTox III: Bridges for Translation

    Article • Toxicological Sciences, October 2016, Oxford University Press (OUP)

    Ronald N. Hines

  9. Integration of Life-Stage Physiologically Based Pharmacokinetic Models with Adverse Outcome Pathways and Environmental Exposure Models to Screen for Environmental Hazards

    Article • Toxicological Sciences, May 2016, Oxford University Press (OUP)

    Dr Tamara Tal, Dr Nicole Kleinstreuer, Ronald N. Hines

  10. Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models

    Article • The Journal of Pediatric Pharmacology and Therapeutics, May 2016, Pediatric Pharmacy Advocacy Group

    Ronald N. Hines

  11. Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver

    Article • Drug Metabolism and Disposition, April 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  12. Oxidative stress-responsive transcription factor NRF2 is not indispensable for the human hepatic Flavin-containing monooxygenase-3 (FMO3) gene expression in HepG2 cells

    Article • Toxicology in Vitro, March 2016, Elsevier

    Dr. José E Manautou, Ronald N. Hines

  13. Role of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny

    Article • Drug Metabolism and Disposition, February 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  14. Age-Dependent Human Hepatic Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2) Postnatal Ontogeny

    Article • Drug Metabolism and Disposition, January 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  15. Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin

    Article • Pediatric Research, November 2015, Nature

    Ronald N. Hines

  16. Use of the RISK21 roadmap and matrix: human health risk assessment of the use of a pyrethroid in bed netting

    Article • Critical Reviews in Toxicology, October 2015, Informa Healthcare

    Ronald N. Hines

  17. Raising the Bar for Reproducible Science at the U.S. Environmental Protection Agency Office of Research and Development

    Article • Toxicological Sciences, March 2015, Oxford University Press (OUP)

    Ronald N. Hines

  18. Human Hepatic UGT2B15 Developmental Expression

    Article • Toxicological Sciences, June 2014, Oxford University Press (OUP)

    Ronald N. Hines

  19. Tolerance to Acetaminophen Hepatotoxicity in the Mouse Model of Autoprotection Is Associated with Induction of Flavin-Containing Monooxygenase-3 (FMO3) in Hepatocytes

    Article • Toxicological Sciences, June 2014, Oxford University Press (OUP)

    Dr. José E Manautou, Ronald N. Hines

  20. Developmental expression of drug metabolizing enzymes: Impact on disposition in neonates and young children

    Article • International Journal of Pharmaceutics, August 2013, Elsevier

    Ronald N. Hines

  21. Toll-like receptor genetic variants are associated with Gram-negative infections in VLBW infants

    Article • Journal of Perinatology, July 2013, Nature

    Ronald N. Hines

  22. Hepatobiliary Disposition of 17-OHPC and Taurocholate in Fetal Human Hepatocytes: A Comparison with Adult Human Hepatocytes

    Article • Drug Metabolism and Disposition, November 2012, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  23. A TIR domain receptor–associated protein (TIRAP) variant SNP (rs8177374) confers protection against premature birth

    Article • Journal of Perinatology, October 2012, Nature

    Ronald N. Hines

  24. Amine Oxidases and Reductases

    Article • May 2012, Wiley

    Ronald N. Hines

  25. Age-Dependent Expression of Human Drug-Metabolizing Enzymes

    Article • January 2012, Wiley

    Ronald N. Hines

  26. A TLR5 (g.1174C > T) variant that encodes a stop codon (R392X) is associated with bronchopulmonary dysplasia

    Article • Pediatric Pulmonology, November 2011, Wiley

    Ronald N. Hines

  27. Prenatal and Postnatal Expression of Glutathione Transferase ζ 1 in Human Liver and the Roles of Haplotype and Subject Age in Determining Activity with Dichloroacetate

    Article • Drug Metabolism and Disposition, October 2011, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  28. The NFKB1 (g.-24519delATTG) Variant is Associated with Necrotizing Enterocolitis (NEC) in Premature Infants

    Article • Journal of Surgical Research, July 2011, Elsevier

    Ronald N. Hines

  29. Hepatic differentiation of amniotic epithelial cells

    Article • Hepatology, April 2011, Wiley

    Ronald N. Hines

  30. Human and environmental health challenges for the next decade (2010–2020)

    Article • Critical Reviews in Toxicology, September 2010, Taylor & Francis

    Ronald N. Hines

  31. Approaches for Assessing Risks to Sensitive Populations: Lessons Learned from Evaluating Risks in the Pediatric Population

    Article • Toxicological Sciences, September 2009, Oxford University Press (OUP)

    Ronald N. Hines

  32. Human hepatic CYP2B6 developmental expression: The impact of age and genotype

    Article • Biochemical Pharmacology, July 2009, Elsevier

    Ronald N. Hines

  33. Differential regulation of human hepatic flavin containing monooxygenase 3 (FMO3) by CCAAT/enhancer-binding protein β (C/EBPβ) liver inhibitory and liver activating proteins

    Article • Biochemical Pharmacology, July 2008, Elsevier

    Ronald N. Hines

  34. Developmental Changes in Human Liver CYP2D6 Expression

    Article • Drug Metabolism and Disposition, May 2008, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  35. The ontogeny of drug metabolism enzymes and implications for adverse drug events

    Article • Pharmacology & Therapeutics, May 2008, Elsevier

    Ronald N. Hines

  36. Novel CYP2C9 Promoter Variants and Assessment of Their Impact on Gene Expression

    Article • Molecular Pharmacology, February 2008, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  37. Regulatory Polymorphisms and their Contribution to Interindividual Differences in the Expression of Enzymes Influencing Drug and Toxicant Disposition

    Article • Drug Metabolism Reviews, January 2008, Taylor & Francis

    Ronald N. Hines

  38. Identification and Functional Analysis of a Novel Human CYP2E1 Far Upstream Enhancer

    Article • Molecular Pharmacology, March 2007, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  39. Phase I Biotransformation Reactions-Flavin Monooxygenase

    Article • January 2007, Elsevier

    Ronald N. Hines

  40. Mechanisms Regulating HumanFMO3Transcription

    Article • Drug Metabolism Reviews, January 2007, Taylor & Francis

    Ronald N. Hines

  41. Ontogeny of human hepatic cytochromes P450

    Article • Journal of Biochemical and Molecular Toxicology, January 2007, Wiley

    Ronald N. Hines

  42. Identification and Functional Analysis of Common Human Flavin-Containing Monooxygenase 3 Genetic Variants

    Article • Journal of Pharmacology and Experimental Therapeutics, October 2006, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  43. Epirubicin Glucuronidation and UGT2B7 Developmental Expression

    Article • Drug Metabolism and Disposition, September 2006, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  44. Pharmacogenomics and the Future of Drug Therapy

    Article • Pediatric Clinics of North America, August 2006, Elsevier

    Ronald N. Hines

  45. Enzyme-Mediated Protein Haptenation of Dapsone and Sulfamethoxazole in Human Keratinocytes: II. Expression and Role of Flavin-Containing Monooxygenases and Peroxidases

    Article • Journal of Pharmacology and Experimental Therapeutics, July 2006, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  46. Enzyme-Mediated Protein Haptenation of Dapsone and Sulfamethoxazole in Human Keratinocytes: I. Expression and Role of Cytochromes P450

    Article • Journal of Pharmacology and Experimental Therapeutics, July 2006, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  47. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: A case study with toluene

    Article • Toxicology and Applied Pharmacology, July 2006, Elsevier

    Ronald N. Hines

  48. Population-Based Analysis of Methadone Distribution and Metabolism Using an Age-Dependent Physiologically Based Pharmacokinetic Model

    Article • Journal of Pharmacokinetics and Pharmacodynamics, June 2006, Springer Science + Business Media

    Ronald N. Hines

  49. Developmental and tissue-specific expression of human flavin-containing monooxygenases 1 and 3

    Article • Expert Opinion on Drug Metabolism & Toxicology, February 2006, Informa Healthcare

    Ronald N. Hines

  50. A Tiered Approach to Life Stages Testing for Agricultural Chemical Safety Assessment

    Article • Critical Reviews in Toxicology, January 2006, Taylor & Francis

    Ronald N. Hines

  51. The Role of Flavin-Containing Monooxygenase (FMO) in the Metabolism of Tamoxifen and Other Tertiary Amines

    Article • Drug Metabolism Reviews, January 2006, Taylor & Francis

    Ronald N. Hines

  52. Developmental Expression of Aryl, Estrogen, and Hydroxysteroid Sulfotransferases in Pre- and Postnatal Human Liver

    Article • Journal of Pharmacology and Experimental Therapeutics, December 2005, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  53. Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development

    Article • Pharmacogenomics, December 2005, Future Medicine

    Ronald N. Hines

  54. MOLECULAR MECHANISMS REGULATING HUMAN CYP4B1 LUNG-SELECTIVE EXPRESSION

    Article • Drug Metabolism and Disposition, May 2005, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  55. SP1 AND SP3 REGULATE BASAL TRANSCRIPTION OF THE HUMAN CYP2F1 GENE

    Article • Drug Metabolism and Disposition, April 2005, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  56. Discovery of Novel Flavin-Containing Monooxygenase 3 (FMO3) Single Nucleotide Polymorphisms and Functional Analysis of Upstream Haplotype Variants

    Article • Molecular Pharmacology, April 2005, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  57. DIFFERENCES IN FMO2*1 ALLELIC FREQUENCY BETWEEN HISPANICS OF PUERTO RICAN AND MEXICAN DESCENT

    Article • Drug Metabolism and Disposition, September 2004, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  58. Two distinct classes of CCAAT box elements that bind nuclear factor-Y/?-actinin-4: potential role in human CYP1A1 regulation

    Article • Toxicology and Applied Pharmacology, September 2004, Elsevier

    Ronald N. Hines

  59. NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine

    Article • Birth Defects Research Part B Developmental and Reproductive Toxicology, January 2004, Wiley

    Martin Keszler, Ronald N. Hines

  60. Developmental Expression of Human Hepatic CYP2C9 and CYP2C19

    Article • Journal of Pharmacology and Experimental Therapeutics, November 2003, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  61. Developmental Expression of the Major Human Hepatic CYP3A Enzymes

    Article • Journal of Pharmacology and Experimental Therapeutics, September 2003, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  62. Human Hepatic CYP2E1 Expression during Development

    Article • Journal of Pharmacology and Experimental Therapeutics, September 2003, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines, Laura Goodman

  63. PUBLICATION OF STAND-ALONE SINGLE NUCLEOTIDE POLYMORPHISM (SNP) DISCOVERY DATA

    Article • Drug Metabolism and Disposition, August 2003, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  64. Genetic Variability at the Human FMO1 Locus: Significance of a Basal Promoter Yin Yang 1 Element Polymorphism (FMO1*6)

    Article • Journal of Pharmacology and Experimental Therapeutics, June 2003, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  65. Workshop Overview: Use of Genomic Data in Risk Assessment

    Article • Toxicological Sciences, April 2003, Oxford University Press (OUP)

    Ronald N. Hines

  66. Biochemical and Clinical Aspects of the Human Flavin-Containing Monooxygenase Form 3 (FMO3) Related to Trimethylaminuria

    Article • Current Drug Metabolism, April 2003, Bentham Science Publishers

    Ronald N. Hines

  67. Trichloroethylene Decreases Heat Shock Protein 90 Interactions with Endothelial Nitric Oxide Synthase: Implications for Endothelial Cell Proliferation

    Article • Toxicological Sciences, March 2003, Oxford University Press (OUP)

    Ronald N. Hines

  68. Characterization of the Human LungCYP2F1Gene and Identification of a Novel Lung-specific Binding Motif

    Article • Journal of Biological Chemistry, February 2003, American Society for Biochemistry & Molecular Biology (ASBMB)

    Ronald N. Hines

  69. Genetics and Susceptibility to Toxic Chemicals: Do You (or Should You) Know Your Genetic Profile?

    Article • Journal of Pharmacology and Experimental Therapeutics, January 2003, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  70. Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis

    Article • Toxicology and Applied Pharmacology, January 2003, Elsevier

    Ronald N. Hines

  71. Alternative Processing of the Human FMO6 Gene Renders Transcripts Incapable of Encoding a Functional Flavin-Containing Monooxygenase

    Article • Molecular Pharmacology, August 2002, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  72. The Ontogeny of Human Drug-Metabolizing Enzymes: Phase II Conjugation Enzymes and Regulatory Mechanisms: Table 1

    Article • Journal of Pharmacology and Experimental Therapeutics, February 2002, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  73. The Ontogeny of Human Drug-Metabolizing Enzymes: Phase I Oxidative Enzymes: Table 1

    Article • Journal of Pharmacology and Experimental Therapeutics, February 2002, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Ronald N. Hines

  74. Human Hepatic Flavin-Containing Monooxygenases 1 (FMO1) and 3 (FMO3) Developmental Expression

    Article • Pediatric Research, February 2002, Nature

    Ronald N. Hines

  75. Ethnic differences in allelic frequency of two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities

    Article • Pharmacogenetics, January 2002, Wolters Kluwer Health

    Ronald N. Hines

  76. GENETIC POLYMORPHISMS OF FLAVIN-CONTAINING MONOOXYGENASE (FMO)

    Article • Drug Metabolism Reviews, January 2002, Taylor & Francis

    Ronald N. Hines

  77. Induction of cytochrome P450 1A1 gene expression, oxidative stress, and genotoxicity by carbaryl and thiabendazole in transfected human HepG2 and lymphoblastoid cells22Abbreviations: AhR, aryl hydrocarbon receptor; CAT, chloramphenicol acetyl transfera...

    Article • Biochemical Pharmacology, February 2001, Elsevier

    Ronald N. Hines

  78. Ethnic Differences in Human Flavin-Containing Monooxygenase 2 (FMO2) Polymorphisms: Detection of Expressed Protein in African-Americans

    Article • Toxicology and Applied Pharmacology, November 2000, Elsevier

    Ronald N. Hines

  79. Diflubenzuron, a Benzoyl-Urea Insecticide, Is a Potent Inhibitor of TCDD-Induced CYP1A1 Expression in HepG2 Cells

    Article • Toxicology and Applied Pharmacology, May 2000, Elsevier

    Ronald N. Hines

  80. ROLE OF CANONICAL GLUCOCORTICOID RESPONSIVE ELEMENTS IN MODULATING EXPRESSION OF GENES REGULATED BY THE ARYLHYDROCARBON RECEPTOR*

    Article • Drug Metabolism Reviews, January 1999, Taylor & Francis

    Ronald N. Hines

  81. A Genetic Polymorphism in the Regulatory Sequences of HumanCYP2E1:Association with Increased Chlorzoxazone Hydroxylation in the Presence of Obesity and Ethanol Intake

    Article • Toxicology and Applied Pharmacology, September 1998, Elsevier

    Ronald N. Hines

  82. Functional characterization of the human CYP1A1 negative regulatory element: modulation of Ah receptor mediated transcriptional activity

    Article • Carcinogenesis, May 1998, Oxford University Press (OUP)

    Ronald N. Hines

  83. Further Characterization of the Major and Minor RabbitFMO1Promoters and Identification of both Positive and Negative Distal Regulatory Elements

    Article • Archives of Biochemistry and Biophysics, October 1997, Elsevier

    Ronald N. Hines

  84. Variation in Induction of Human Placental CYP2E1: Possible Role in Susceptibility to Fetal Alcohol Syndrome?

    Article • Toxicology and Applied Pharmacology, June 1997, Elsevier

    Ronald N. Hines

  85. Identification of Multiple Rabbit Flavin-Containing Monooxygenase Form 1 (FMO1) Gene Promoters and Observation of Tissue-Specific DNase I Hypersensitive Sites

    Article • Archives of Biochemistry and Biophysics, December 1996, Elsevier

    Ronald N. Hines

  86. VARIATION IN INDUCTION OF PLACENTAL CYTOCHROME P4502E1: POSSIBLE ROLE IN SUSCEPTIBILITY TO FETAL ALCOHOL SYNDROME? • 484

    Article • Pediatric Research, April 1996, Nature

    Ronald N. Hines

  87. Differential expression and activity of flavin-containing monooxygenases in euryhaline and stenohaline flatfishes indicates potential osmoregulatory role

    Article • Comparative Biochemistry and Physiology Part C Pharmacology Toxicology and Endocrinology, October 1995, Elsevier

    Ronald N. Hines

  88. Developmental regulation of flavin-containing monooxygenase (FMO) isoforms 1 and 2 in pregnant rabbit

    Article • Chemico-Biological Interactions, April 1995, Elsevier

    Ronald N. Hines

  89. In vitro binding and functional studies comparing the human CYPIAI negative regulatory element with the orthologous sequences from rodent genes

    Article • Carcinogenesis, January 1995, Oxford University Press (OUP)

    Ronald N. Hines

  90. Characterization of hepatic flavin monooxygenase from the marine teleost turbot (Scophthalmus maximus L.)

    Article • Xenobiotica, January 1995, Taylor & Francis

    Ronald N. Hines

  91. The Mammalian Flavin-Containing Monooxygenases: Molecular Characterization and Regulation of Expression

    Article • Toxicology and Applied Pharmacology, March 1994, Elsevier

    Ronald N. Hines

  92. A Nomenclature for the Mammalian Flavin-Containing Monooxygenase Gene Family Based on Amino Acid Sequence Identities

    Article • Archives of Biochemistry and Biophysics, January 1994, Elsevier

    Ronald N. Hines

  93. Expression of CYP1A1 Gene in Patients With Lung Cancer: Evidence for Cigarette Smoke-Induced Gene Expression in Normal Lung Tissue and for Altered Gene Regulation in Primary Pulmonary Carcinomas

    Article • JNCI Journal of the National Cancer Institute, August 1990, Oxford University Press (OUP)

    Ronald N. Hines

  94. Immunochemical and molecular biological studies on human placental cigarette smoke-inducible cytochrome P-450-dependent monooxygenase activities

    Article • Toxicology, May 1990, Elsevier

    Ronald N. Hines

  95. Altered Regulation of the Cytochrome P4501A1 Gene: Novel Inducer-Independent Gene Expression in Pulmonary Carcinoma Cell Lines

    Article • JNCI Journal of the National Cancer Institute, December 1989, Oxford University Press (OUP)

    Ronald N. Hines

  96. Glucocorticoid regulation of the rat cytochrome P450c (P450IA1) gene: Receptor binding within intron I

    Article • Archives of Biochemistry and Biophysics, February 1989, Elsevier

    Ronald N. Hines

  97. Production of growth factors related to fibroblast growth factor and platelet-derived growth factor by human embryonal carcinoma cells

    Article • In Vitro Cellular & Developmental Biology - Animal, December 1988, Springer Science + Business Media

    Ronald N. Hines

  98. Identification of multiple regulatory elements on the human cytochrome P450IA1 gene

    Article • Carcinogenesis, January 1988, Oxford University Press (OUP)

    Ronald N. Hines

  99. Induction of cytochrome P-450IA1 gene expression in human breast tumour cell lines

    Article • Chemico-Biological Interactions, January 1988, Elsevier

    Ronald N. Hines

  100. The molecular biology of the polycyclic aromatic hydrocarbon inducible cytochrome P-450; the past is prologue

    Article • BioEssays, January 1986, Wiley

    Ronald N. Hines

  101. Implication of the "4S" polycyclic aromatic hydrocarbon binding protein in the transregulation of rat cytochrome P-450c expression

    Article • Biochemistry, December 1985, American Chemical Society (ACS)

    Ronald N. Hines

  102. Demonstration of microsomal oxygenation of the benzo ring of 6-nitrobenzo[a]pyrene by thin-layer chromatography

    Article • Journal of Chromatography A, January 1984, Elsevier

    Ronald N. Hines

  103. Molecular induction by phenobarbital of a rat hepatic form of cytochrome P-450: Expression of a 4-kilobase messenger RNA

    Article • Archives of Biochemistry and Biophysics, December 1983, Elsevier

    Ronald N. Hines

  104. Inhibition of metabolism-mediated cytotoxicity by 1,1-disubstituted hydrazines in mouse mastocytoma (line p815) cells

    Article • Biochemical Pharmacology, September 1982, Elsevier

    Ronald N. Hines

  105. The molecular cloning of cytochrome P-450c information

    Article • Archives of Biochemistry and Biophysics, December 1981, Elsevier

    Ronald N. Hines

  106. EVIDENCE FOR INHIBITORY COMPLEXES FORMED WITH CYTOCHROME P-450 AND A METABOLITE OF 1,1-DISUBSTITUTED HYDRAZINES

    Article • January 1980, Elsevier

    Ronald N. Hines

  107. The role of Pi in glycolytic inhibition of calcium ion uptake by ELD ascites tumor cells

    Article • Biochimica et Biophysica Acta (BBA) - Biomembranes, March 1977, Elsevier

    Ronald N. Hines